NUP214 and acute myeloid leukemia: Of note, a patient with AML associated with a DEK-NUP214 fusion displayed a remarkable response to treatment with Selinexor in a phase I clinical trial [42], underscoring the clinical relevance of the Crm1/NUP214 interaction.